Jove
Visualize
Contact Us

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

159
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
159
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

214
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
214
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

127
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
127
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

202
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
202
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

290
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
290
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of a survey questionnaire for screening of obstructive airway disease by primary care physicians.

Lung India : official organ of Indian Chest Society·2026
Same author

Aminophylline in acute exacerbation of COPD: Utility and treatment effects in hypercapnic respiratory failure (ACUTE): A pilot observational study.

Lung India : official organ of Indian Chest Society·2025
Same author

Risk factors for asthma across India: Results from global asthma network (GAN) phase I study.

Lung India : official organ of Indian Chest Society·2025
Same author

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Pulmonary therapy·2024
Same author

Position statement of the Indian Chest Society on reinstatement of the Respiratory Medicine department in undergraduate medical colleges in India.

Lung India : official organ of Indian Chest Society·2023
Same author

Global Asthma Network Phase I, India: Results for allergic rhinitis and eczema in 127,309 children and adults.

The journal of allergy and clinical immunology. Global·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 22, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.7K

Biologics and Tuberculosis Preventive Therapy.

Aloke G Ghoshal1, Arup Halder2

  • 1Director, National Allergy Asthma Bronchitis Institute, Kolkata, West Bengal, India.

The Journal of the Association of Physicians of India
|March 15, 2025
PubMed
Summary
This summary is machine-generated.

Biologics and JAK inhibitors increase tuberculosis risk. Screening and treating latent TB before starting these therapies significantly lowers TB incidence, though it doesn't eliminate it.

More Related Videos

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

10.5K
Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

860

Related Experiment Videos

Last Updated: May 22, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.7K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

10.5K
Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

860

Area of Science:

  • Immunology
  • Infectious Diseases
  • Pharmacology

Background:

  • Biologics have transformed systemic inflammatory disorder treatment.
  • Increased infection susceptibility is a primary side effect of biologics.
  • Anti-TNF agents and other biologics, alongside JAK inhibitors, elevate the risk of tuberculosis (TB) reactivation.

Purpose of the Study:

  • To review the risk of TB reactivation associated with biologics and JAK inhibitors.
  • To discuss current guidelines and the need for tailored approaches to TB screening and treatment.
  • To highlight the importance of integrating TB risk management into clinical practice for patients on immunosuppressive therapies.

Main Methods:

  • Literature review of studies on biologics, JAK inhibitors, and TB reactivation.
  • Analysis of existing national and international guidelines for TB screening and prevention.
  • Discussion of the Indian National Tuberculosis Elimination Programme (NTEP) guidelines for programmatic management of TB preventive therapy (PMTPT).

Main Results:

  • Biologics, particularly anti-TNF agents, and JAK inhibitors are associated with a significant risk of TB reactivation in patients with latent TB infection (LTBI).
  • Proactive LTBI screening and treatment before initiating these therapies substantially reduce TB disease incidence.
  • Existing guidelines vary globally due to socioeconomic factors and TB endemicity, necessitating context-specific application.

Conclusions:

  • Implementing LTBI screening and treatment is crucial for mitigating TB risk in patients receiving biologics or JAK inhibitors.
  • While effective, current strategies do not entirely eliminate TB reactivation risk.
  • Clinicians must stay informed about the differential TB risks of various biologics and adapt screening protocols accordingly.